カテゴリ： GlobalData, アメリカ, 企業調査

The Broad Institute Inc：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：The Broad Institute Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12332
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation is a non-profit research organization that conducts genomic research for treatment of human diseases. The organization transforms medicine by utilizing systematic approaches in biological sciences, to speed up the understanding and treatment of disease. It offers research to assemble molecular components and define the biological circuits that underlie cellular responses. The organization also operates various research projects uncover the molecular basis of major inherited diseases and unearth all the mutations that underlie different cancer types. Broad Institute is headquartered in Cambridge, Massachusetts, the US.

The Broad Institute Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
The Broad Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
The Broad Institute Inc, Medical Devices Deals, 2012 to YTD 2018 11
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
DefiniGen Enters into Licensing Agreement with Broad Institute 15
Beam Therapeutics Enters into Licensing Agreement with Broad Institute 16
Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 17
Eisai Enters into Research Agreement with Broad Institute 18
Cohen Veterans Bioscience Partners with Stanley Center for Psychiatric Research 19
Broad Institute Genomic Services Partners with Takeda Pharma 20
Beryllium Enters into Development Agreement with Broad Institute for MCL-1 platform 21
Bayer HealthCare Expands Co-Development Agreement with Broad Institute for Cardiovascular Therapies 22
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 23
Eisai Enters into Research Agreement with Broad Institute 24
Tetra Discovery Enters Into Co-Development Agreement With Stanley Center For Schizophrenia Therapeutics 25
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 26
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 27
Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 29
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 30
AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 31
Licensing Agreements 32
Celsius Therapeutics Enters into Licensing Agreement with Broad Institute 32
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 33
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 35
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 37
Applied Stemcell Enters into licensing Agreement with Broad Institute 39
Albany Molecular Research Enters into Licensing Agreement with Broad Institute 40
Evotec Enters into Licensing Agreement with Broad Institute 41
Transposagen Biopharma Enters into Licensing Agreement with Broad Institute 42
Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 43
Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 44
GE Healthcare Life Sciences Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 45
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 46
Sage Labs Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 47
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 48
The Broad Institute Inc – Key Competitors 49
The Broad Institute Inc – Key Employees 50
The Broad Institute Inc – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Recent Developments 52
Strategy And Business Planning 52
Oct 10, 2017: Broad Institute launches Merkin Institute for Transformative Technologies in Healthcare 52
Legal and Regulatory 53
Sep 13, 2018: US Appeals Court upholds ruling on CRISPR patents in favour of Broad Institute 53
Government and Public Interest 55
Sep 10, 2018: Protein analysis uncovers new cancer subtypes for medulloblastoma 55
Aug 15, 2018: New genome analysis scores risk of serious common diseases 57
Jul 24, 2018: Researchers identify immune system mechanism that regulates inflammation 58
Apr 24, 2018: A Leading Method in Human Genetics Studies May Need to Be Reconsidered, as Researchers Discover Significant Distortions 59
Apr 02, 2018: Disease-Causing Mobile Element Identified with SMRT Sequencing, Validated with CRISPR 60
Mar 19, 2018: Metastatic Prostate Cancer Project Explores a New Approach to Genomics Research 61
Dec 20, 2017: CRISPR therapy preserves hearing in progressive deafness model 63
Sep 28, 2017: Neuro-Immune Crosstalk in Allergic Asthma 65
Product News 67
May 18, 2017: Cohen Veterans Bioscience and the Broad Institute’s Stanley Center for Psychiatric Research with PTSD researchers from the Psychiatric Genomics Consortium Announce Initial Findings from Largest Study of Genetic Markers for Post-Traumatic Stress Disorder 67
Jan 09, 2018: Broad Institute releases open-source GATK4 software for genome analysis, optimized for speed and scalability 68
Other Significant Developments 70
Aug 13, 2018: Predicting risk for common deadly diseases from millions of genetic variants 70
Jul 10, 2017: Broad Institute of MIT and Harvard Joins Discussions to Create Worldwide CRISPR-Cas9 Licensing Pool 72
May 24, 2017: BGI to work with Broad Institute, Intel and Alibaba Cloud to provide free access to GATK4 on BGI Online 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
The Broad Institute Inc, Pharmaceuticals & Healthcare, Key Facts 2
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
The Broad Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
The Broad Institute Inc, Deals By Therapy Area, 2012 to YTD 2018 10
The Broad Institute Inc, Medical Devices Deals, 2012 to YTD 2018 11
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
DefiniGen Enters into Licensing Agreement with Broad Institute 15
Beam Therapeutics Enters into Licensing Agreement with Broad Institute 16
Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 17
Eisai Enters into Research Agreement with Broad Institute 18
Cohen Veterans Bioscience Partners with Stanley Center for Psychiatric Research 19
Broad Institute Genomic Services Partners with Takeda Pharma 20
Beryllium Enters into Development Agreement with Broad Institute for MCL-1 platform 21
Bayer HealthCare Expands Co-Development Agreement with Broad Institute for Cardiovascular Therapies 22
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 23
Eisai Enters into Research Agreement with Broad Institute 24
Tetra Discovery Enters Into Co-Development Agreement With Stanley Center For Schizophrenia Therapeutics 25
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 26
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 27
Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 29
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 30
AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 31
Celsius Therapeutics Enters into Licensing Agreement with Broad Institute 32
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 33
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 35
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 37
Applied Stemcell Enters into licensing Agreement with Broad Institute 39
Albany Molecular Research Enters into Licensing Agreement with Broad Institute 40
Evotec Enters into Licensing Agreement with Broad Institute 41
Transposagen Biopharma Enters into Licensing Agreement with Broad Institute 42
Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 43
Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 44
GE Healthcare Life Sciences Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 45
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 46
Sage Labs Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 47
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 48
The Broad Institute Inc, Key Competitors 49
The Broad Institute Inc, Key Employees 50
The Broad Institute Inc, Other Locations 51
The Broad Institute Inc, Subsidiaries 51

List of Figures
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
The Broad Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
The Broad Institute Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[The Broad Institute Inc：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Actinogen Medical Ltd (ACW)-製薬・医療分野：企業M&A・提携分析
    Summary Actinogen Medical Ltd (Actinogen), formerly Actinogen Ltd is a biotechnology company that undertakes research in Alzheimer’s disease and other chronic neurodegenerative diseases. The company’s xanamem is a novel drug under development for the treatment of Alzheimer's disease. It develops dru …
  • Industrias Nucleares do Brasil SA：企業の戦略的SWOT分析
    Industrias Nucleares do Brasil SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Alcami Corporation：企業の戦略・SWOT・財務情報
    Alcami Corporation - Strategy, SWOT and Corporate Finance Report Summary Alcami Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Exelon Corporation：企業のM&A・事業提携・投資動向
    Exelon Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Exelon Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Macquarie Group Ltd
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tyler Technologies Inc (TYL)：企業の財務・戦略的SWOT分析
    Tyler Technologies Inc (TYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • CRH Medical Corp (CRH)：医療機器：M&Aディール及び事業提携情報
    Summary CRH Medical Corp (CRH Medical), formerly Medsurge Medical Products Corp, is a medical device company that offers treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It offers topical ointments and creams including preparation H …
  • Nanovis Inc：医療機器：M&Aディール及び事業提携情報
    Summary Nanovis Inc (Nanovis) is a medical device company that develops and markets tissue regenerating implants for bone and soft tissues. The company offers products such as implant nanosurfaces, implantable scaffolds and cervical plate, lumbar PEEK interbody systems, pedicle screws, injectable bi …
  • Bilfinger Tebodin BV：企業の戦略的SWOT分析
    Bilfinger Tebodin BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • ESAB Holdings Ltd：企業の戦略・SWOT・財務情報
    ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • QuickLogic Corp (QUIK)：企業の財務・戦略的SWOT分析
    QuickLogic Corp (QUIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dr. Reddy’s Laboratories Limited：企業の戦略・SWOT・財務情報
    Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report Summary Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • China Petrochemical Corp：企業のM&A・事業提携・投資動向
    China Petrochemical Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Petrochemical Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Takaful Emarat – Insurnace (P.S.C)：企業の戦略・SWOT・財務情報
    Takaful Emarat - Insurnace (P.S.C) - Strategy, SWOT and Corporate Finance Report Summary Takaful Emarat - Insurnace (P.S.C) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • New Standard Energy Ltd (NSE)：企業の財務・戦略的SWOT分析
    Summary New Standard Energy Ltd (NSE), formerly Hawk Resources Ltd, is an oil and gas exploration and production company. The company carries out acquisition, exploration, and develops oil and gas; and hydrocarbon properties. It holds interest in production and development project in the Eagle Ford …
  • Central Electricity Generating Co：企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Companhia Energetica de Sao Paulo (CESP6)-エネルギー分野：企業M&A・提携分析
    Summary Companhia Energetica de Sao Paulo (CESP) is a state-owned integrated electric utility. It plans, constructs, and operates electric energy generation and commercialization systems. The company generates energy from hydro source. CESP owns power plants at at Rio Paran, Rio Paraibuna, and Rio J …
  • Petroleo Brasileiro SA (PETR4)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petroleo Brasileiro SA (Petrobras) is an integrated oil and gas company. Its major businesses include exploration and production, refining, marketing, trade and transportation of oil and gas. The company also conducts biofuel, petrochemical, natural gas, electricity and chemical businesses, …
  • Holidaybreak Ltd：企業の戦略・SWOT・財務情報
    Holidaybreak Ltd - Strategy, SWOT and Corporate Finance Report Summary Holidaybreak Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nectar Lifesciences Ltd (NECLIFE)：企業の財務・戦略的SWOT分析
    Summary Nectar Lifesciences Ltd (NecLife) is a research driven pharmaceutical company that manufactures active pharmaceutical ingredients (APIs). The company provides contract research and manufacturing services such as process development and optimization, process scale up and validation, multi kil …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆